United States Single Dose Nasal Spray Devices Market 2025: Industry Developments, Future Growth, Share & Industry Insights | Aptar Pharma, Nemera, Rexam Healthcare Packaging, Silgan Dispensing Systems, West Pharmaceutical

Global Single Dose Nasal Spray Devices Market reached US$ 335.5 million in 2023 and is expected to reach US$ 537.1 million by 2033, growing at a CAGR of 6.5% during the forecast period 2025-2033.

According to DataM Intelligence Comprehensive Report has released its latest report on the "Single Dose Nasal Spray Devices Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/single-dose-nasal-spray-devices-market?sg

Industry Latest News 2025:

✅ 05 Mar 2025 - USA: FDA expanded ARS Pharmaceuticals' epinephrine nasal spray neffy to include patients weighing 15-30 kg (1 mg dose).

✅ 16 Apr 2025 - USA: FDA approved Neurelis' diazepam nasal spray VALTOCO for short-term treatment of seizure clusters in patients 2 years and older (expanded pediatric approval).

✅ 01 Oct 2025 - USA: ARS Pharmaceuticals filed an antitrust suit alleging AptarGroup monopolized supply of critical single-dose nasal spray components used in neffy.

✅ 24 Jun 2025 - Japan: Aculys Pharma received marketing approval for Spydia® (diazepam nasal spray) for status epilepticus / seizure rescue.

✅ 19 Sep 2025 - Japan: PMDA granted approval for ARS Pharmaceuticals' neffy® (1 mg and 2 mg) as a needle-free emergency treatment for allergic reactions (anaphylaxis) in Japan.

✅ 01 Jan 2025 - Korea (policy): South Korea's MFDS implemented an overhaul of its drug-approval/review system (rolling reviews, dedicated teams) to speed approvals - affecting device/drug combination reviews including nasal products.

✅ 30 Jun 2025 - Korea (product): LUCA AICELL launched a CE-certified, MFDS-cleared drug-free protective nasal spray in South Korea (regulatory clearance reported).

✅ 26 Sep 2025 - Korea (supply): MFDS granted lot/shipment approval for returning intranasal flu vaccine (FluMist) doses for national distribution - signals resumed infl uenza nasal spray activity in Korea.

✅ 18 Jul 2025 - Europe (UK): UK approved EURneffy® (adrenaline/epinephrine nasal spray) as a needle-free emergency treatment for anaphylaxis (first-of-its-kind approval in the UK).

✅ (CHMP / 2025 filing) - Europe (regulatory): ARS/partners pursued EMA/CHMP filings and variations for neffy (1.0 mg filing for lower-weight children submitted in Q1 2025; EU/Canada commercialization rights with ALK noted).

✅ 15 Oct 2025 - Global/Europe-Asia M&A: Viatris completed acquisition of Aculys Pharma (including rights/portfolio that cover Spydia in Japan and APAC territories).

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/single-dose-nasal-spray-devices-market?sg

Market Geographical Share:

North America holds the dominant share of the global market, supported by strong healthcare infrastructure, early adoption of innovative nasal drug delivery systems, and a high prevalence of respiratory and central nervous system (CNS)-related disorders. The U.S. continues to lead the region due to growing usage of self-administered treatments and a robust presence of device manufacturers.

Asia-Pacific is projected to witness the fastest growth rate over the coming years. Increasing healthcare expenditure, expanding pharmaceutical manufacturing capabilities in Japan, South Korea, China, and India, and growing consumer awareness about needle-free drug delivery are key regional accelerators.

Market Growth Drivers:

✅ Rising Demand for Needle-Free Drug Delivery: Increasing patient preference for convenient and pain-free administration methods is a major factor propelling market growth.

✅ Growing Applications in Emergency and Chronic Therapies: Single dose nasal sprays are being increasingly used for rapid delivery of drugs in conditions like migraines, seizures, and opioid overdose, enhancing their clinical importance.

✅ Advancements in Formulation and Device Design: Ongoing innovations in spray mechanics, dose precision, and compatibility with biologics are improving treatment efficacy and user compliance.

✅ Expansion of Vaccine Delivery via Nasal Route: The development of intranasal vaccines for influenza, COVID-19, and other respiratory diseases has opened new opportunities for single-dose devices.

✅ Favorable Regulatory Approvals and Commercial Launches: Increasing approvals for combination products (drug + device) and supportive regulatory guidelines are accelerating market penetration.

Segments Covered in the Beverage Premix Market:

By Product Type - Liquid Nasal Sprays, Sterile solutions, Saline sprays, Powder Nasal Sprays

By Material Type - Plastic, Polyethylene (PE), Polypropylene (PP), Glass

By Application - Allergic Rhinitis, Nasal Congestion, Sinusitis, Influenza and Vaccines, Others

By End User - Hospitals, Clinics, Home Care Settings, Others

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=single-dose-nasal-spray-devices-market?sg

Major Key Players: Aptar Pharma, Nemera, BD (Becton, Dickinson and Company), H&T Presspart, Bespak by Recipharm, Rexam Healthcare Packaging, Silgan Dispensing Systems, West Pharmaceutical Services, Inc, Gerresheimer AG, 3M Drug Delivery Systems.

✅ H&T Presspart - Established global specialist in respiratory & nasal drug-delivery components; a leading supplier of precision single-use actuators and filling/assembly support (strong commercial footprint in Europe/North America, typically positioned among the top tier of component suppliers rather than as an integrated drug-product CDMO).

✅ Bespak (by Recipharm) - Bespak is a market leader for unit-dose nasal platforms (NasaDose/Unidose style technologies) and a CDMO for finished single-dose nasal products heavily active in clinical/commercial supply and investing to scale single-dose capabilities, making it one of the largest contract suppliers in this segment.

✅ Rexam Healthcare Packaging (now Nemera historically) - The business formerly known as Rexam Healthcare Devices (now operating under names acquired/restructured, e.g., Nemera) historically held significant share in healthcare/packaging device supply; today its legacy position means it remains an important competitor in primary healthcare packaging even if product lines and corporate names have shifted.

✅ Silgan Dispensing Systems - Supplier of the Monodose Nasal System and other single-use nasal dispensers a key alternative to pump/valve incumbents, actively positioned as a direct device supplier to pharma clients and cited in litigation/industry news as a material competitor for single-dose components.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.